Abstract:The APOE4 allele is the strongest genetic risk factor for sporadic Alzheimer""s disease (AD). While APOE4 is strongly associated with amyloid-beta (Aβ) accumulation, its relationship with tau accumulation is less understood. Studies evaluating the role of APOE4 on tau accumulation have shown conflicting results, particularly regarding the independence of these associations from Aβ load. To clarify the relations between APOE4, Aβ and tau, we examined three independent longitudinal cohorts (the Swedish BioFINDER-1, BioFINDER-2 and WRAP cohorts) in which participants had cross-sectional and longitudinal measures of tau tangles (tau-PET; temporal meta-ROI and entorhinal) or soluble p-tau (p-tau217), Aβ-PET and APOE genotype. The study included a total of 1370 cognitively unimpaired (CU) and 449 mild cognitive impairment (MCI) subjects, followed longitudinally with tau-PET and p-tau217. APOE4 carriers accounted for 40.2-50% of the cohorts. Different linear regressions (cross-sectional) and linear mixed-effect models (longitudinal) with tau measures as outcomes were fitted to test the effect of APOE4 as independent predictor, as well as in combination with baseline Aβ load or the interaction term between APOE4 and Aβ load. All models included age, sex and cognitive status as covariates. We found no independent effects of the APOE4 carriership on insoluble tau aggregates in either cohort (BioFINDER-2 or WRAP), both on cross-sectional and longitudinal tau-PET levels in the temporal meta-ROI, when Aβ was present in the model (p=0.531-0.949). Aβ alone was the best predictor of insoluble tau accumulation, and there was no interaction between APOE4 and Aβ on tau-PET. Similarly, no independent effects of the APOE4 carriership on baseline (p=0.683-0.708) and longitudinal (p=0.188-0.570) soluble p-tau217 were observed when Aβ was included in the model in BioFINDER-1 and WRAP. No interaction between APOE4 and Aβ on soluble p-tau217 was observed. Furthermore, mediation analysis revealed that Aβ load fully mediated most associations between APOE4 and tau (46-112%, either cross-sectional or longitudinal tau-PET or soluble p-tau217). In the largest cohort (BioFINDER-2), looking at APOE4 groups based on the number of ϵ4 alleles, we found an interaction between APOE4 homozygotes only and Aβ on tau-PET levels at baseline and over time. In conclusion, although APOE4 is strongly associated with Aβ aggregation, it seems to be minimally associated with longitudinal changes in soluble or insoluble p-tau levels at a given level of Aβ pathology, confirming the primacy of Aβ in driving tau pathology.

Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy

Impact of APOE genotype on prion-type propagation of tauopathy

The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation

Impact of sex and APOE-ε4 genotype on patterns of regional brain atrophy in Alzheimer's disease and healthy aging

Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis

The influence of APOEε4 on the pTau interactome in sporadic Alzheimer's disease

The relationship between ApoE4 and lipid dysregulation in glia of the PS19 mouse model of tauopathy

Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia

APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression

Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits

APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease

Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy

Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4‐induced brain pathology

Analysis of early effects of human APOE isoforms on Alzheimer's disease and type III hyperlipoproteinemia pathways using knock-in rat models with humanized APP and APOE

Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice

Modeling Alzheimer’s Disease in Mouse without Mutant Protein Overexpression: Cooperative and Independent Effects of Aβ and Tau

Opposing Effects of ApoE2 and ApoE4 on Glycolytic Metabolism in Neuronal Aging Supports a Warburg Neuroprotective Cascade against Alzheimer's Disease

Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease

APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta